The complaint

The case is Bayer HealthCare LLC and Bayer HealthCare Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. and MSN Laboratories Pvt. Ltd., No. 1:26-cv-01502 (D. Del.), filed November 19, 2026, ECF No. 1. The complaint says this is an action for patent infringement under the patent laws of the United States, Title 35, United States Code, and for a declaratory judgment of patent infringement under 28 U.S.C. 2201 and 2202, arising out of ANDA No. 221953. Bayer HealthCare LLC is a limited liability company organized under the laws of Delaware, and Bayer HealthCare Pharmaceuticals Inc. is a corporation organized under the laws of Delaware. Each has a place of business in Whippany, New Jersey. The complaint alleges, on information and belief, that MSN Pharmaceuticals Inc. is a corporation organized under the laws of Delaware with its principal place of business in Piscataway, New Jersey; that MSN Laboratories Pvt. Ltd. is a private limited company organized under the laws of India with its principal place of business in Hyderabad, India; and that MSN Pharmaceuticals Inc. is a wholly owned subsidiary of MSN Laboratories Pvt. Ltd. It alleges, on information and belief, that the two defendants acted in concert to prepare and submit ANDA No. 221953. It alleges, on information and belief, that the two defendants contemplate that, upon approval of the ANDA, MSN Laboratories Pvt. Ltd. will manufacture the ANDA product and MSN Pharmaceuticals Inc. will directly or indirectly market, sell, and distribute it throughout the United States, including in Delaware.

The complaint pleads subject-matter jurisdiction under 28 U.S.C. 1331, 1338(a), 2201, and 2202. It alleges, on information and belief, that MSN Pharmaceuticals Inc. has registered to do business in Delaware and has appointed a registered agent in Delaware to accept service of process, and it says MSN Pharmaceuticals Inc. has thus consented to jurisdiction in Delaware. It also alleges, on information and belief, that MSN Laboratories Pvt. Ltd., acting in concert with MSN Pharmaceuticals Inc., filed the ANDA to seek approval to engage in the commercial manufacture, use, offer for sale, sale, and/or importation of the ANDA product in the United States, including in Delaware, and that upon approval the defendants will market, distribute, offer for sale, and/or sell the ANDA product in the United States, including in Delaware, and will derive substantial revenue from the use or consumption of the ANDA product in Delaware. It says MSN has consented to jurisdiction in Delaware in one or more prior cases arising out of the filing of ANDAs, and that MSN has filed counterclaims in such cases. It alleges, on information and belief, that if MSN Laboratories Pvt. Ltd.'s connections with Delaware, including its connections with MSN Pharmaceuticals Inc., are found insufficient to confer personal jurisdiction, then MSN Laboratories Pvt. Ltd. is not subject to jurisdiction in any State's courts of general jurisdiction, and that exercising jurisdiction over it in Delaware is consistent with the United States Constitution and laws, citing Federal Rule of Civil Procedure 4(k)(2). It pleads venue as to each defendant under 28 U.S.C. 1391 and 1400(b).

The ANDA and STIVARGA

The complaint says ANDA No. 221953 seeks approval to manufacture and sell generic versions of Bayer's STIVARGA product before U.S. Patents 8,637,553 (the '553 patent), 9,458,107 (the '107 patent), and 9,957,232 (the '232 patent) expire. It says that by a letter dated October 6, 2026, which it calls the Notice Letter, MSN notified Bayer that MSN had submitted ANDA No. 221953 seeking approval to engage in the commercial manufacture, use and/or sale of regorafenib tablets, 40 mg, which the complaint calls MSN's ANDA Product, before those patents expire. It alleges, upon information and belief, that MSN's ANDA Product is a generic version of STIVARGA. It says the Notice Letter stated that the ANDA product contains regorafenib and that it is a tablet, and that, in connection with the ANDA, MSN had filed a Paragraph IV Certification with respect to each of the three patents. It says MSN had knowledge of the claims of each patent before it filed its Paragraph IV Certification. It says this action is being commenced before the expiration of forty-five days from the receipt of the Notice Letter.

The complaint says STIVARGA, which contains regorafenib, is a kinase inhibitor indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. It is also indicated for patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor who have been previously treated with imatinib mesylate and sunitinib malate, and for patients with hepatocellular carcinoma who have been previously treated with sorafenib. It says Bayer HealthCare Pharmaceuticals Inc. is the holder of NDA No. 203085 for STIVARGA, which has been approved by the FDA. It says that, pursuant to 21 U.S.C. 355, each of the three patents is listed in the Orange Book in connection with STIVARGA.

The '553 patent

The complaint says United States Patent No. 8,637,553, entitled "Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions," was duly and legally issued on January 28, 2014. It says Bayer HealthCare LLC is the assignee of the '553 patent, which has not expired. It says the claims of the '553 patent cover, inter alia, regorafenib and pharmaceutical compositions containing regorafenib. It alleges, on information and belief, that the manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of the ANDA product, including use in accordance with and as directed by MSN's labeling for that product, will infringe one or more claims of the '553 patent, including at least claims 13 and 14. Claim 13 covers a compound of Formula (I). Claim 14 covers a pharmaceutical composition comprising the compound of claim 13 and a physiologically acceptable carrier.

The complaint says that in the Notice Letter, MSN does not contest that the claims of the '553 patent cover its ANDA product, and that the Notice Letter only alleges that the claims are invalid and therefore cannot be infringed. It alleges, on information and belief, that MSN plans and intends to, and will, actively induce infringement of the '553 patent when its ANDA is approved, and that it plans and intends to, and will, do so immediately and imminently upon approval.

The '107 patent

The complaint says United States Patent No. 9,458,107 was duly and legally issued on October 4, 2016, and that Bayer HealthCare LLC is the assignee of the '107 patent, which has not expired. The complaint says the claims of the '107 patent cover, inter alia, regorafenib which is contaminated with one or more anilinic substances, each in an amount equal to or less than 0.05% by weight based on the weight of the regorafenib. It alleges, on information and belief, that the manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of the ANDA product, including use in accordance with and as directed by MSN's labeling, will infringe one or more claims of the '107 patent, including at least claim 1. Claim 1 covers the compound of the formula (I) which is contaminated with one or more anilinic substances, each in an amount equal to or less than 0.05% by weight based on the weight of the compound of the formula (I). The complaint alleges, on information and belief, that MSN plans and intends to, and will, actively induce infringement of the '107 patent when its ANDA is approved, immediately and imminently upon approval.

The '232 patent

The complaint says U.S. Patent No. 9,957,232, entitled "4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate," was duly and legally issued on May 1, 2018, and that Bayer HealthCare LLC is the assignee of the '232 patent, which has not expired. It says the claims of the '232 patent cover, inter alia, regorafenib monohydrate which shows in X-ray diffractometry a peak maximum of the 2 Theta angle of 21.2. It alleges, on information and belief, that the ANDA product contains regorafenib monohydrate as claimed in the '232 patent. It alleges, on information and belief, that the manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of the ANDA product, including use in accordance with and as directed by MSN's proposed labeling, will infringe one or more claims of the '232 patent, including at least claim 19. Claim 19 covers the compound of the formula (II) which shows in the X-ray diffractometry a peak maximum of the 2 Theta angle of 21.2. The complaint alleges, on information and belief, that MSN plans and intends to, and will, actively induce infringement of the '232 patent when its ANDA is approved, immediately and imminently upon approval.

The six counts

Count I is infringement of the '553 patent, Count III is infringement of the '107 patent, and Count V is infringement of the '232 patent. Each alleges that MSN's submission of ANDA No. 221953, for the purpose of obtaining approval to engage in the commercial manufacture, use, offer for sale, and/or sale of the ANDA product, was an act of infringement of that patent under 35 U.S.C. 271(e)(2). Each says that unless MSN is enjoined from infringing that patent and from actively inducing infringement of it, Bayer will suffer irreparable injury, and that Bayer has no adequate remedy at law.

Count II is a declaratory judgment as to the '553 patent, Count IV is a declaratory judgment as to the '107 patent, and Count VI is a declaratory judgment as to the '232 patent. Each arises under the Declaratory Judgment Act, 28 U.S.C. 2201 and 2202. Each alleges, on information and belief, that MSN has made, and will continue to make, substantial preparation in the United States to manufacture, use, sell, offer to sell, and/or import the ANDA product with its proposed labeling before that patent expires. Each says MSN intends to engage in the manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of the ANDA product with its proposed labeling immediately and imminently upon approval, before the patent expires. Each alleges, on information and belief, that pursuant to 35 U.S.C. 271(a) and/or (b), MSN's manufacture, use, sale, or offer for sale within the United States, or importation into the United States, of the ANDA product, including in accordance with its proposed labeling, would constitute infringement of that patent and inducement of infringement. Count II asks for a declaratory judgment that the making, using, sale, offer for sale, and importation into the United States of the ANDA product with its proposed labeling infringes and actively induces infringement of the '553 patent. Counts IV and VI ask for a declaratory judgment that those acts would infringe and actively induce infringement of the '107 patent and the '232 patent.

The relief requested

The prayer asks for a judgment that MSN has infringed the '553 patent, the '107 patent, and the '232 patent. As to each patent, it asks for a judgment that the effective date of any FDA approval for MSN to make, use, offer for sale, sell, market, distribute, or import the ANDA product, or any product or compound which infringes or the use of which infringes that patent, be not earlier than the expiration date of that patent, inclusive of any extension(s) and additional period(s) of exclusivity. It asks for a preliminary and permanent injunction enjoining MSN, and all persons acting in concert with MSN, from making, using, selling, offering for sale, marketing, distributing, or importing the ANDA product, or any product or compound that infringes or the use of which infringes that patent, or the inducement of any of the foregoing, before that expiration date, inclusive of any extension(s) and additional period(s) of exclusivity. It asks for a judgment declaring that those acts, before that expiration date, will infringe and actively induce infringement of that patent. It asks for a declaration that this is an exceptional case and an award of attorneys' fees pursuant to 35 U.S.C. 285, an award of Bayer's costs and expense in this action, and such further and other relief as the court may deem just and proper.

What to watch next

Watch for an answer or a Rule 12 motion. The case can end at any time, including by settlement or voluntary dismissal.